CL2007002514A1 - Composicion farmaceutica liquida que comprende: 0,05-3% de acido alendronico o una sal, 0,02-0,12% de un agente viscosante seleccionado de un grupo definido, un agente saborizante, especialmente naranja, y agua; proceso de preparacion; y su uso para prevenir y/o tratar enfermedades metabolicas oseas. - Google Patents

Composicion farmaceutica liquida que comprende: 0,05-3% de acido alendronico o una sal, 0,02-0,12% de un agente viscosante seleccionado de un grupo definido, un agente saborizante, especialmente naranja, y agua; proceso de preparacion; y su uso para prevenir y/o tratar enfermedades metabolicas oseas.

Info

Publication number
CL2007002514A1
CL2007002514A1 CL2007002514A CL2007002514A CL2007002514A1 CL 2007002514 A1 CL2007002514 A1 CL 2007002514A1 CL 2007002514 A CL2007002514 A CL 2007002514A CL 2007002514 A CL2007002514 A CL 2007002514A CL 2007002514 A1 CL2007002514 A1 CL 2007002514A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
preparation process
water
liquid pharmaceutical
salt
Prior art date
Application number
CL2007002514A
Other languages
English (en)
Inventor
Elisabeth Diaz Liliana
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador Sa filed Critical Gador Sa
Publication of CL2007002514A1 publication Critical patent/CL2007002514A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica líquida estabilizada que comprende ácido alendronico, un agente aumentador de la viscosidad, un agente saborizante y agua; proceso de preparación; y uso para la prevención y/o tratamiento de enfermedades metabólicas óseas tales como osteopatías metabólicas u osteoporosis.
CL2007002514A 2006-09-04 2007-08-29 Composicion farmaceutica liquida que comprende: 0,05-3% de acido alendronico o una sal, 0,02-0,12% de un agente viscosante seleccionado de un grupo definido, un agente saborizante, especialmente naranja, y agua; proceso de preparacion; y su uso para prevenir y/o tratar enfermedades metabolicas oseas. CL2007002514A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06018423A EP1894557B1 (en) 2006-09-04 2006-09-04 Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore

Publications (1)

Publication Number Publication Date
CL2007002514A1 true CL2007002514A1 (es) 2008-01-11

Family

ID=37440291

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007002514A CL2007002514A1 (es) 2006-09-04 2007-08-29 Composicion farmaceutica liquida que comprende: 0,05-3% de acido alendronico o una sal, 0,02-0,12% de un agente viscosante seleccionado de un grupo definido, un agente saborizante, especialmente naranja, y agua; proceso de preparacion; y su uso para prevenir y/o tratar enfermedades metabolicas oseas.

Country Status (14)

Country Link
EP (1) EP1894557B1 (es)
AR (1) AR062596A1 (es)
AT (1) ATE498391T1 (es)
AU (1) AU2007294261B2 (es)
CL (1) CL2007002514A1 (es)
CY (1) CY1111202T1 (es)
DE (1) DE602006020137D1 (es)
DK (1) DK1894557T3 (es)
ES (1) ES2361333T3 (es)
MY (1) MY148248A (es)
PL (1) PL1894557T3 (es)
PT (1) PT1894557E (es)
SI (1) SI1894557T1 (es)
WO (1) WO2008028547A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103191414B (zh) * 2013-03-29 2014-10-22 武汉中博绿亚生物科技有限公司 一种宠物快速吸收的液体钙及其制备方法
CN116616449A (zh) * 2023-06-05 2023-08-22 浙江索契壹营养科技有限公司 一种酸性抗菌体系稳定承载高钙和维生素d的饮液及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof

Also Published As

Publication number Publication date
ATE498391T1 (de) 2011-03-15
WO2008028547A1 (en) 2008-03-13
SI1894557T1 (sl) 2011-04-29
CY1111202T1 (el) 2015-06-11
DE602006020137D1 (de) 2011-03-31
AU2007294261B2 (en) 2012-09-06
PL1894557T3 (pl) 2011-07-29
AU2007294261A1 (en) 2008-03-13
DK1894557T3 (da) 2011-05-30
EP1894557A1 (en) 2008-03-05
MY148248A (en) 2013-03-29
EP1894557B1 (en) 2011-02-16
AR062596A1 (es) 2008-11-19
ES2361333T3 (es) 2011-06-16
PT1894557E (pt) 2011-03-02

Similar Documents

Publication Publication Date Title
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
BR112015014592A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um humano
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
NZ597354A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
MX2011012122A (es) Derivados de tiofeno.
PE20120788A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos
BR112012027092A2 (pt) métodos e composiões para reduzir ou impedir a calcificação vascular durante a terapia de diálise peritoneal
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
BR112012003907A2 (pt) composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês
BR112013029182A2 (pt) método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
WO2011085013A3 (en) Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
PE20060364A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CL2007002514A1 (es) Composicion farmaceutica liquida que comprende: 0,05-3% de acido alendronico o una sal, 0,02-0,12% de un agente viscosante seleccionado de un grupo definido, un agente saborizante, especialmente naranja, y agua; proceso de preparacion; y su uso para prevenir y/o tratar enfermedades metabolicas oseas.
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса